The common core 1 O-glycan structure Gal␤13 3GalNAc-R is the precursor for many extended mucintype O-glycan structures in animal cell surface and secreted glycoproteins. Core 1 is synthesized by the transfer of Gal from UDP-Gal to GalNAc␣1-R by core 1 ␤3-galactosyltransferase (core 1 ␤3-Gal-T). Amino acid sequences from purified rat core 1 ␤3-Gal-T (Ju, T., Cummings, R. D., and Canfield, W. M. (2002) J. Biol. Chem. 277, 169 -177) were used to identify the core 1 ␤3-Gal-T sequences in the human expressed sequence tag data bases. A 1794-bp human core 1 ␤3-Gal-T cDNA sequence was determined by sequencing the expressed sequence tag and performing 5-rapid amplification of cDNA ends. The core 1 ␤3-Gal-T predicts a 363-amino acid type II transmembrane protein. Expression of both the fulllength and epitope-tagged soluble forms of the putative enzyme in human 293T cells generated core 1 ␤3-Gal-T activity that transferred galactose from UDP-Gal to GalNAc␣1-O-phenyl, and a synthetic glycopeptide with Thrlinked GalNAc and the product was shown to have the core 1 structure. Northern analysis demonstrated widespread expression of core 1 ␤3-Gal-T in tissues with a predominance in kidney, heart, placenta, and liver. Highly homologous cDNAs were identified and cloned from rat, mouse, Drosophila melanogaster, and Caenorhabditis elegans, suggesting that the enzyme is widely distributed in metazoans. The core 1 ␤3-Gal-T sequence has minimal homology with conserved sequences found in previously described ␤3-galactosyltransferases, suggesting this enzyme is only distantly related to the known ␤3-galactosyltransferase family.
stepwise transfer of sugars from sugar nucleotide donors to acceptor substrates through the sequential action of glycosyltransferases (1) . The mucin-type O-glycans are classified according to the presence of a series of core structures. At least eight different O-glycans core structures have been described so far, with core 1 and 2 structures being the most common in non-mucin glycoproteins and core 1-4 being the most common in mucins (2) .
The core 1 structure Gal␤133GalNAc␣1-R is synthesized from GalNAc␣1-R by the action of core 1 UDP-galactose:GalNAc-␣-R ␤1,3-galactosyltransferase (core 1 ␤3-Gal-T, 1 EC 2.4.1.122), where R is Ser/Thr. The core 1 ␤3-Gal-T activity was first described in porcine and ovine submaxillary glands (3) and has been found in most cell types and mammalian tissues (reviewed in Refs. 1 and 4). It is likely, however, that the activity of core 1 ␤3-Gal-T is regulated during cell differentiation and development. The core 1 structure is an intermediate in the synthesis of most extended O-glycan structures and may be further modified by the addition of GlcNAc or sialic acid. Interestingly, the unsubstituted core 1 disaccharide Gal␤133GalNAc␣1-R is recognized as a cancer-associated antigen (T-or Thomsen-Friedenreich antigen) (5) . The T-antigen is found in several types of cancers, including breast, bladder, and colon carcinomas.
Alterations in core 1 ␤3-Gal-T activity may play an important role in other diseases, such as Tn syndrome and IgA nephropathy (6 -11) . It is thought that these diseases may result from somatic mutations in core 1 ␤3-Gal-T, thereby causing expression of the truncated GalNAc-␣-R (known as the Tn antigen). The Tn antigen is recognized by a naturally occurring Tn antibody in adult serum and in Tn syndrome results in polyagglutinability of blood cells (6, 12) or persistent mixed field polyagglutination (13) . A similar mechanism may underlie IgA nephropathy (14) . The hinge region of IgA 1 contains at least five O-glycosylation sites normally modified by the core 1 structure or its sialylated derivative (15) . In the absence of core 1 ␤3-Gal-T, reduced terminal galactosylation of O-glycans may lead to a defective clearance of IgA, resulting in mesangial deposition and glomerular injury. Although these diseases might be predicted to result from deficiency of core 1 ␤3-Gal-T, the exact pathogenesis is unknown, because the key enzyme, core 1 ␤3-Gal-T, has not been amenable to molecular analysis. * This work was supported in part by National Institutes of Health Grant RO1 AI48075-01 (to R. D. C.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The nucleotide sequence (s) In the present study, we describe the cloning and expression of a human cDNA encoding core 1 ␤3-Gal-T, using the amino acid sequence of the purified enzyme from rat liver, as described in the accompanying article (see Ju, et al. (33) ). The human cDNA was then used to identify homologs in rat, mouse, Drosophila melanogaster and Caenorhabditis elegans. The core 1 ␤3-Gal-T sequences described here have minimal homology to previously described ␤3-galactosyltransferases, suggesting that core 1 ␤3-Gal-T is a distantly related member of this large enzyme family.
EXPERIMENTAL PROCEDURES
Materials-Rat and human multiple tissue Northern blots, Marathon ready cDNA from human, rat, and mouse, and Marathon RACE kits were obtained from CLONTECH (Palo Alto, CA Support Media were from Pierce. PSGL-1 glycopeptide (4-GP-1), GluTyr-Glu-Tyr-Leu-Asp-Tyr-Asp-Phe-Leu-Pro-Glu-(GalNAc␣1-O-Thr)-Glu-Pro-Pro-Glu-Met and having the GalNAc-substituted Thr, as indicated, was synthesized as described (16) .
DNA Sequencing-DNA sequencing was performed using T. aquaticus DNA polymerase and the PerkinElmer Life Sciences dye-labeled T. aquaticus terminators using the manufacturer's protocols.
Isolation and Sequencing of the Human Core 1 ␤3-Gal-T cDNA-The rat liver core 1 ␤3-Gal-T was purified as described in the accompanying article (33) , and an amino-terminal peptide sequence was identified. BlastP searching of the NCBI EST data base using this terminal peptide sequence identified a rat EST, AI059600, and this clone contains the internal tryptic peptide sequence identified for the purified rat liver enzyme. BlastN searching with the rat EST sequence and BlastP searching with the rat liver enzyme internal tryptic peptide sequence identified the same human EST, T10488. The human EST was sequenced and found to contain a 1.6-kb insert incomplete at the 5Ј end. The human core 1 ␤3-Gal-T cDNA was completed by 5Ј-RACE using primers AP1 and CANF273 5Ј-CTTTATGTTGGCTAGAATCTGC-3Ј with human placental marathon-ready cDNA as template. Amplification was carried out at 94°C, 1 min; 94°C, 30 s; 68°C, 2 min for 35 cycles; then 68°C, 10 min. The 450-bp product purified using a QIAQuick gel extraction kit was ligated into PCR 2.1 and sequenced.
Construction of an Expression Vector Encoding Wild-type Human Core 1 ␤3-Gal-T-Oligonucleotides 5Ј-GATCCACCATGGCCTCTA-AATCCTGGCTG-3Ј and 5Ј-AATTCAGCCAGGATTTAGAGGCCATG-GTG-3Ј were annealed and ligated to a 155-bp ApoI/XbaI fragment from the cloned 5Ј-RACE product; a 1.5-kb XbaI/XhoI fragment from T10488 and BamHI/XhoI cut pcDNA 3.1(ϩ) was ligated, generating phCore1-WT.
Construction of an Expression Vector Expressing a Soluble, Epitopetagged Version of Human Core 1 ␤3-Gal-T-An expression vector encoding a soluble epitope-tagged core 1 ␤3-Gal-T (phCore1-SF) was constructed by ligating annealed oligonucleotides with the sequences 5Ј-GATCCTCATGCAAGG-3Ј and 5Ј-TTGCATGAG-3Ј, a 1,584-bp BsmI/ XhoI fragment from EST T10488 and vector fragment of pcDNA 3.1(ϩ)-TH with BamHI/XhoI digestion. Expression of this plasmid in eukaryotic cells results in the secretion of core 1 ␤3-Gal-T in which the epitope tag EDQVDPRLIDGK is fused to Asp-45 in the human core 1 ␤3-Gal-T sequence.
Protein Assay-Protein was determined by the BCA assay (Pierce) according to the manufacturer's protocol using bovine serum albumin as a standard.
Assay for Activity of Core 1 ␤3-Gal-T-Core 1 ␤3-Gal-T was assayed as described in the accompanying article (33) .
Preparation of HPC4-UltraLink TM -Twenty five mg of HPC4 monoclonal antibody was dissolved in 20 ml of 0.1 M MOPS and 0.6 M sodium citrate, pH 7.5, and coupled to 0.6 g of UltraLink TM beads at room temperature for 1 h, followed by blocking with 3 M ethanolamine (1 h, 20°C). The resin was then washed with 1 M NaCl and equilibrated with 25 mM Tris-HCl, pH 7.4, 150 mM NaCl, and 1 mM CaCl 2 .
Expression of Wild-type and Soluble Core 1 ␤3-Gal-T-Human 293T cells in 100-mm dishes were transiently transfected with wild-type and soluble expression vectors using FuGENE TM 6 according to the manufacturer's protocol and cultured in Dulbecco's modified Eagle's media containing 10% fetal calf serum. Cells were harvested at 24, 48, and 72 h, washed twice with cold TBS (25 mM Tris-HCl, pH 7.4, 150 mM NaCl), and sonicated on ice (10 s, 3 times, Branson Cell Disruptor model 185, setting 5) in 300 -500 l of TBS containing 1 mM phenylmethylsulfonyl fluoride, 1 mM benzamidine HCl, 2 g/ml leupeptin. Cell homogenates were centrifuged at 1,000 ϫ g for 10 min, solubilized in 0.5% Triton X-100, and assayed for core 1 ␤3-Gal-T. For expression of soluble core 1 ␤3-Gal-T, media were harvested at the indicated times and directly assayed.
For generating stably transfected cell lines expressing the core 1 ␤3-Gal-T to characterize the possible post-translational modifications of the enzyme, we used both CHO K1 and Lec1-CHO cells. These cells were cultured in Dulbecco's modified Eagle's media containing 10% fetal bovine serum and were transfected with the soluble expression vector using FuGENE TM 6, as described above for the human 293T cells. The transfected cells were selected with 600 g/ml gentamicin sulfate in the same media. After 2-3 weeks of selection, the stably expressing cell lines were obtained, and media from the cells were collected.
Capture of Soluble Core 1 ␤3-Gal-T on HPC4-UltraLink-HPC4-UltraLink (100 l) equilibrated with 50 mM Tris-HCl, pH 7.2, 100 mM NaCl, 1 mM CaCl 2 was incubated with 500 l of media containing human 293T cells expressing the HPC4 epitope-tagged core 1 ␤3-Gal-T for 2 h at 4°C. The beads were collected by centrifugation (2,000 ϫ g, 2 min) and washed three times with 500 l of 50 mM Tris-HCl, pH 7.4, 1 M NaCl, and 1 mM CaCl 2 . The beads were then washed once with equilibration buffer and directly assayed for core 1 ␤3-Gal-T using GalNAc␣1-O-phenyl as the acceptor.
Western Blot of Human HPC4 Epitope-tagged Soluble Core 1 ␤3-Gal-T Expressed in Different Mammalian Cell Lines-Twenty five l of media from transiently transfected 293T, stably transfected CHO K1, and stably transfected Lec1-CHO cells were electrophoresed on an SDS-PAGE (4 -20%) and transferred to a nitrocellulose membrane. After blocking with 5% milk, the membrane was incubated with 10 ml of 10 g/ml HPC-4 monoclonal antibody (IgG1) at room temperature for 1 h. The membrane was then washed twice with a low salt solution (25 mM Tris-HCl, pH 7.4, containing 1 mM CaCl 2 and 150 mM NaCl) and then washed three times with a high salt solution (25 mM Tris-HCl, pH 7.4, containing 1 mM CaCl 2 and 500 mM NaCl). The membrane was then incubated with horseradish peroxidase-conjugated, goat anti-mouse IgG at room temperature for 1 h, washed as above with low and high salt buffers, and then incubated with 6 ml of HighSignal West Pico Chemiluminescent Substrate at room temperature for 1 min. The blot was exposed to a BioMax film (Kodak) for 30 s, and the film was developed.
Identification of the Product Generated by the HPC4 Epitope-tagged Core 1 ␤3-Gal-T-The HPC4 epitope-tagged core 1 ␤3-Gal-T in 40 ml of media from the stably transfected CHO-K1 cell line was captured by incubation with 200 l of HPC4-Ultralink beads at 4°C for 3 h. After washing with 50 ml of low salt solution and 50 ml of high salt solution (see above), 50 l of the beads was incubated with 100 g of PSGL-1 glycopeptide (4-GP-1) in 100 l containing 100 mM MES, pH 6.5, 500 M UDP-[ 3 H]Gal (150,000 cpm), 20 mM MnCl 2 , and 2.0 mM ATP. As a positive control, a reaction was set up the same as above except that pure rat liver core 1 ␤3-Gal-T (2 nmol/h) was used as the enzyme source instead of protein captured onto beads, and 0.2% of Triton X-100 was added. After a 16-h incubation at 37°C, the reaction mixtures were loaded onto C 18 cartridges (500 mg) following the standard core 1 ␤3-Gal-T assay (33). The bound material was eluted with 2.5 ml of methanol, and a 0.125-ml portion was mixed with 5 ml of Scintiverse-BD and radioactivity determined in a liquid scintillation counter.
The residual 2.375 ml from each sample was dried in a speed-vac concentrator. The dried material was redissolved in 200 l of 50 mM Tris-HCl, pH 7.0, containing 150 mM NaCl. Twenty l of the redissolved material was treated with 5 milliunits of O-glycosidase at 37°C for 24 h. One-half of this reaction mixture was then loaded onto C 18 Cartridges (500 mg). The cartridges were washed with 10 ml of water, and bound material was eluted with 2 ml of methanol. The eluates were mixed with 18 ml of Scintiverse-BD and counted.
Northern Blot Analysis-A human multiple tissue Northern blot was probed with a 32 P-labeled 147-bp EcoRI fragment corresponding to bp 179 -325 of the human core 1 ␤3-Gal-T cDNA. The probe was random hexamer-labeled to Ͼ1 ϫ 10 9 cpm/g DNA (17, 18) and hybridized using standard techniques (19) overnight at 65°C in PerfectHyb TM solution. After hybridization, the blots were washed twice in 2ϫ SSC 0.1% SDS at room temperature for 20 min and 0.1ϫ SSC, 0.1% SDS at 65°C twice for 30 min, and then autographed.
Isolation of Rat Core 1 ␤3-Gal-T cDNA-Rat EST AI059600 identified as described above was sequenced (930 bp) and found to be incomplete at the 3Ј end. The cDNA was completed by nested 3Ј-RACE using CANF254 (5Ј-TGGACTTCAATGCAGATTCTAGCCAAC-3Ј) and AP1 as primers and rat liver marathon-ready cDNA as template. PCR was performed for 35 cycles at 94°C, 1 min; 94°C, 30 s; 53°C, 1 min; 72°C, 2 min for 35 cycles. The second round reaction was performed with primers CANF312 (5Ј-AGCAGGGATACATGAGTGGAGGAG-3Ј) and AP2, and a 1:100 dilution of the first round reaction as template. The reaction was incubated at 94°C, 30 s; 53°C, 1 min; 70°C, 1 min for 25 cycles followed by 72°C for 10 min. The 682 bp band was excised, cloned into PCR 2.1, and sequenced.
Isolation of Mouse cDNA Encoding Core 1 ␤3-Gal-T-A mouse EST (AI060759) was identified by a BlastN search using the rat core 1 ␤3-Gal-T. The 426-bp EST was sequenced and found to be incomplete at the 5Ј end. The 5Ј portion of the cDNA was completed by nested 5Ј-RACE using primers CANF334 (5Ј-AGACCACTTATGTTCTGCTT-TCAGGGG-3Ј), AP1, and mouse liver marathon-ready cDNA incubated at 94°C, 1 min; 94°C, 30 s; 64°C, 1 min; 72°C, 2 min for 35 cycles. Nested PCR was performed with a 1:100 dilution of the first reaction as template and primers CANF335 (5Ј-AACTGCGATATCAGAACAG-CATCCAGG-3Ј) and AP2 incubated at 94°C, 1 min; 94°C, 30 s; 70°C, 2 min for 25 cycles followed by 70°C, 10 min. The 1098-bp product was excised and cloned into PCR 2.1 and sequenced.
Isolation of C. elegans Core 1 ␤3-Gal-T cDNA-BlastP searching using the human core 1 ␤3-Gal-T protein sequence demonstrated the C. elegans gene C38H2.2 was highly homologous. Core 1 ␤3-Gal-T was found using its cDNA with 1.26 kb as predicted. For isolation of its cDNA, two PCRs covering both 5Ј and 3Ј ends with 170-bp overlap were carried out using primers based on the cDNA from C38H2.2 using C. elegans cDNA library. The 5Ј end PCR primer set utilized the forward primer 5Ј-CCACCATGAAGAGACGGTTTTGTCG-3Ј and the reverse primer 5Ј-CGGTGAATGAGCCAATAG-3Ј. The 3Ј end PCR primer set utilized the forward primer 5Ј-AGGATGCAGAACTCCCAG-3Ј and the reverse primer 5Ј-GCTTATACAGCAACTTCCGGCC-3Ј. The PCR products were ligated with PCR 2.1 vector and cloned and sequenced. The PCR product of the 3Ј end perfectly matched the cDNA predicted by C38H2.2. By contrast, the PCR product of the 5Ј end only matched partially. Using 5Ј end matched sequence of this PCR product allowed identification of a C. elegans EST clone (C41813) by a BlastN dbEST search. Analysis of the PCR product from the 5Ј end of cDNA predicted to be encoded by C38H2.2 and comparison of that sequence to the EST sequence of the EST clone C41813 confirmed that the 5Ј end of the cDNA predicted in the BlastP search from C38H2.2 is incorrect. Therefore, we redesigned primers based on the EST clone C41813 sequence. The primer set utilized the forward primer 5Ј-CCACCATGGCAAACT-GGCCACGTGTTTC-3Ј and the reverse primer 5Ј-CGGTGAATGAGC-CAATAG-3Ј. With these primers for the 5Ј end of the EST clone, we performed a PCR with the cDNA library of C. elegans and generated a 620-bp product. Analysis of the sequences of the EST clone C41813 and this PCR product, along with the sequence of the 3Ј-half PCR product, gave the sequence of the full-length cDNA for the C. elegans core 1 ␤3-Gal-T.
Alignment of Core 1 ␤3-Gal-T Homologs-The translated sequences were aligned using the program ClustalW as implemented in MacVector 7.0. (20) searching with the rat amino-terminal protein sequence (33) identified EST clone AI059600. The predicted translation of this DNA sequence also contained the tryptic peptide sequence identified previously. This putative rat core 1 ␤3-Gal-T was then used to identify homologous human EST sequences.
RESULTS

Identification of a Rat Core 1 ␤3-Gal-T EST-BlastN
Identification and Characterization of the Human Core 1 ␤3-Gal-T-A partial human EST was identified by BlastP searching with the rat EST and the tryptic peptide sequence. The 5Ј portion of the cDNA was amplified by 5Ј-RACE and sequenced as described under "Experimental Procedures." The 1794-bp cDNA sequence predicts an open reading frame of 1089 bp, predicting a protein of 363 amino acids (Fig. 1A) . (The human mRNA sequence has been deposited in GenBank TM as accession number AF155582.) Analysis of the hydropathy plot by the method of Kyte and Doolittle (21) demonstrated a hydrophobic region between amino acids 7 and 32, predicting that the protein is a type II transmembrane protein as has been seen for almost all mammalian glycosyltransferases described previously (Fig. 1B) . The determined amino-terminal sequence indicated only the initiator methionine had been removed, again consistent with a type II transmembrane topology. The predicted mass of the mature human core 1 ␤3-Gal-T is 42,068 daltons, in excellent agreement with the observed mass of the rat enzyme (33) . Analysis of the deduced protein sequence indicated no consensus sites for N-glycosylation.
Construction of Plasmids Encoding Wild-type and an HPC4 Epitope-tagged Soluble Form of Core 1 ␤3-Gal-T-To express the human wild-type core 1 ␤3-Gal-T, the Kozak sequence was optimized by the insertion of a -CCACC-sequence before the initiator ATG (22) . The modified cDNA was cloned into the mammalian expression vector pcDNA3.1(ϩ) generating the plasmid designated phCore1-WT. We also constructed a second plasmid designated phCore1-SF that encoded an HPC4 epitope-tagged soluble form of core 1 ␤3-Gal-T in which the cDNA sequences encoding the cytoplasmic and transmembrane domains were replaced by the human transferrin signal peptide and the HPC4 epitope as described under "Experimental Procedures."
Expression of phCore1-WT and phCore1-SF-To confirm the cloned cDNA-encoded core 1 ␤3-Gal-T, the cDNA was expressed by transient transfection of the human embryonic kidney cell line, 293T. Cells were transfected with phCore1-WT, phCore1-SF, or the empty vector, pcDNA 3.1(ϩ), as described under "Experimental Procedures." Cell monolayers were harvested at 24, 48, or 72 h after transfection; the cells were disrupted with Triton X-100, and core 1 ␤3-Gal-T activity was measured toward the acceptor GalNAc␣1-O-phenyl. The ␤3-Gal-T activity was modestly and progressively increased when compared with cells transfected with empty vector yielding an ϳ3.3-fold increase at 72 h (Fig. 2) . The modest increases were in part because the parent cell line expresses significant core 1 ␤3-Gal-T activity. To exploit the observation that little core 1 ␤3-Gal-T activity was present in tissue culture media, a plasmid expressing a soluble form of the enzyme lacking its cytoplasmic and transmembrane domain was constructed and expressed in the same cell line. Core 1 ␤3-Gal-T activity in the media from these transfected cells was ϳ37-fold above control media from cells transfected with the empty vector after 72 h (Fig. 3A) , further supporting the possibility that this cDNA encodes core 1 ␤3-Gal-T.
To demonstrate conclusively the cloned cDNA represents the structural gene for core 1 ␤3-Gal-T rather than an activator or co-factor, the cDNA was modified to direct the synthesis of an epitope-tagged protein. Plasmid phCore1-SF was engineered to modify the amino terminus of core 1 ␤3-Gal-T with the 12-amino acid epitope for the monoclonal antibody HPC4 (23, 24) . Incubation of 293T cell media following transfection with phCore1-SF with HPC4-UltraLink resulted in capture of the core 1 ␤3-Gal-T activity on beads containing HPC4 and depletion of the activity from the media (Fig. 3B) . Direct assay of the HPC4-UltraLink for core 1 ␤3-Gal-T activity demonstrated the enzyme was active when bound to the antibody.
To confirm the isolation, purity, and size of the recombinant core 1 ␤3-Gal-T containing the HPC4 epitope was expressed in human 293T cells, wild-type CHO cells (CHO-K-1), and a mutant CHO cell line (CHO Lec1), which lacks N-acetylglucosaminyltransferase I and therefore exclusively synthesizes high mannose-type N-glycan and no complex-or hybrid-type Nglycans containing sialic acid or galactose. The HPC4-tagged recombinant protein in media from these cells was analyzed by Western blot (Fig. 4A) . The enzyme from all three cell lines migrated as a defined band at ϳ39 kDa (Fig. 4B) , which is in agreement with the predicted size of the truncated, soluble protein containing an HPC4 epitope with the calculated size of 38,726.7 daltons. The sequence of the vertebrate core 1 ␤3-Gal-T predicts an absence of N-glycosylation sequons. Thus, the data in Fig. 4A confirm the absence of N-glycosylation on the protein and suggest that there are few, if any, other types of post-translational modifications affecting the size of the recombinant protein. It should be noted that the results shown in Fig. 4A represent the size of the recombinant, soluble core 1 ␤3-Gal-T in reducing SDS-PAGE. In non-reducing SDS-PAGE the recombinant protein behaved as a species of ϳ80 kDa, consistent with its occurrence as a disulfide-bonded dimer (data not shown). Because this recombinant is truncated and therefore lacks the transmembrane domain and the two Cys residues in the transmembrane domain, the results suggest that disulfide-based dimerization of the recombinant protein does not require those Cys residues.
FIG. 1. cDNA and deduced protein sequence of the human core 1 ␤3-Gal-T. A, the nucleotide and deduced amino acid sequence of human core 1 ␤3-Gal-T is shown. The putative transmembrane domain is singly underlined. The portions of the sequence that correspond to the identified amino-terminal and internal tryptic peptide of the purified rat liver core 1 ␤3-Gal-T (33) are indicated by the double underlining with two changes Asn 3 Asp and Gln 3 Glu. (The sequence of rat protein in Fig. 7 has the exact sequence of these peptides.) B, hydrophilicity plot of human core 1 ␤3-Gal-T. Hydrophilicity, as determined by the method of Kyte and Doolittle (21) , is plotted versus the amino acid sequence of human core 1 ␤3-Gal-T. A window size of 7 was used.
FIG. 2.
Expression of wild-type core 1 ␤3-Gal-T. Human 293T cells were transfected with an expression plasmid containing the wildtype full-length core 1 ␤3-Gal-T cDNA or a control vector. Cells were harvested at 24, 48, and 72 h and assayed for the expression of core 1 ␤3-Gal-T activity.
Identification of the Product of HPC4 Epitope-tagged Core 1
␤3-Gal-T-To demonstrate that epitope-tagged core 1 ␤3-Gal-T synthesizes core 1 O-glycan, a PSGL-1 glycopeptide modeled after the extreme amino terminus of the human P-selectin glycoprotein ligand (PSGL-1) designated 4-GP-1 was utilized. The glycopeptide 4-GP-1 has the sequence Glu-Tyr-Glu-TyrLeu-Asp-Tyr-Asp-Phe-Leu-Pro-Glu-(GalNAc␣1-O-Thr)-GluPro-Pro-Glu-Met with a single GalNAc-substituted Thr, as indicated. 4-GP-1 was incubated with HPC4 beads captured epitope-tagged core 1 ␤3-Gal-T and UDP-[ 3 H]Gal in the absence of Triton X-100. 4-GP-1 was 3 H-galactosylated ϳ100% by the captured core 1 ␤3-Gal-T, and activity was equivalent to that obtained with the purified rat liver core 1 ␤3-Gal-T (Fig. 5) . After treatment of the products of both enzyme preparations with O-glycanase, the product was quantitatively cleaved from the peptide, and only background radioactivity was re-bound to the C 18 column (Fig. 5 ). These results demonstrate that the O-glycan products generated by the HPC4 epitope-tagged core 1 ␤3-Gal-T and the purified rat liver core 1 ␤3-Gal-T were sensitive to O-glycanase and represent the disaccharide Gal␤1-3GalNAc (Fig. 5) .
Expression Pattern of Core 1 ␤3-Gal-T in Human Tissues-To determine the tissues in which core 1 ␤3-Gal-T is expressed, a multiple tissue Northern blot was probed with a random hexamer-labeled 147-bp probe derived from the core 1 ␤3-Gal-T cDNA. Two different transcripts of 7.0 and 2.0 kb FIG. 3 . Expression of soluble epitope-tagged core 1 ␤3-Gal-T. A, human 293T cells were transfected with an expression vector containing a soluble HPC4 epitope-tagged core 1 ␤3-Gal-T cDNA or a control vector. At 24, 48, and 72 h following transfection, the media were sampled and assayed for core 1 ␤3-Gal-T activity. B, capture of epitopetagged core 1 ␤3-Gal-T on anti-epitope HPC4-UltraLink beads. Media from A were collected 72 h after transfection and were incubated with HPC4-UltraLink beads. Following a wash, the beads and unbound material in the supernatant were assayed for core 1 ␤3-Gal-T activity. were identified, with the 2.0-kb transcript predominating (Fig.  6A) . Expression was especially high in heart, kidney, liver, and placenta, moderate in brain and skeletal muscle, and relatively low in other tissues examined.
The 2.0-kb message agrees well with the predicted size of a polyadenylated 1794-bp transcript. The 7.0-kb message could represent an alternatively spliced message or a partially spliced polyadenylated species. High stringency washing failed to displace the probe with the 7.0-kb transcript, strongly suggesting this message contains the same sequences (not shown).
Identification of Putative Core 1 ␤3-Gal-T Sequences in Other Species-Putative core 1 ␤3-Gal-T sequences from rat (Rattus norvegicus), mouse (Mus musculus), fruit fly (D. melanogaster), and nematode (C.s elegans) were identified by data base searching.
The 930-bp rat EST clone AI059600 identified above was sequenced and found to be incomplete at the 3Ј end. The remaining 3Ј sequence was cloned by nested 3Ј-RACE as described under "Experimental Procedures" (25) . The sequence predicts a protein of 363 amino acids that is 89.8% identical to the human sequence (Fig. 7) . (The rat mRNA sequence has been deposited in GenBank TM as accession number AF157963.) The rat EST clone was used to probe a rat multiple tissue Northern blot that demonstrated ϳ7.0-kb transcripts in liver, skeletal muscle, lung, spleen, and kidney. Interestingly, an ϳ2.0-kb transcript was found uniquely in testis (Fig. 6B) . The finding of different transcript sizes in different tissues was comparable with the results of the Northern blot of human tissues.
The mouse sequence was identified by BlastN searching using the rat cDNA sequence. The sequence was completed by nested 5Ј-RACE as described under "Experimental Procedures." The sequence predicts a 363-amino acid protein highly homologous to the rat sequence and 90% identical to the human sequence (Fig. 7) . (The mouse mRNA sequence has been deposited in GenBank TM as accession number AF157962.) The nematode genome was searched by BlastP using the human protein sequence. This search identified a putative C. elegans gene product, C38H2.2, with homology to the human gene (Fig. 7) . To confirm that the predicted C. elegans gene is actually transcribed, two separate PCRs were performed for the 5Ј-and 3Ј-halves of the predicted cDNA using C. elegans cDNA library of mixed developmental stages as a template. As described in detail under "Experimental Procedures," the sequence of the PCR product from the 3Ј-half (744 bp) perfectly matched the predicted sequence from the gene C38H2.2. By contrast, the PCR product from 5Ј-half of the cDNA generated FIG. 5 . Identification of the product of epitope-tagged core 1 ␤3-Gal-T. The HPC4 epitope-tagged core 1 ␤3-Gal-T in media from the stably transfected CHO-K1 cell line was captured by HPC4-Ultralink beads. The bound protein was incubated with 100 g of the glycopeptide acceptor 4-GP-1 and UDP-[ 3 H]Gal in the presence of 20 mM MnCl 2 . The purified rat liver core 1 ␤3-Gal-T was used as a positive control. The product glycopeptides of the reactions were adsorbed to C 18 cartridges (500 mg) following the standard core 1 ␤3-Gal-T assay (33) , and the bound material was eluted with 2.5 ml of methanol. A portion of the eluted material (0.125 ml) was mixed with 5 ml of Scintiverse BD, and radioactivity was determined in a liquid scintillation counter. A portion of the residual material was treated with 5 milliunits of O-glycosidase at 37°C for 24 h. A portion of this treated material was then loaded to C 18 Cartridges (500 mg), and the bound radioactivity was determined as above.
FIG. 6.
Northern blot analysis of human core 1 ␤3-Gal-transferase transcripts. A, the human core 1 ␤3-Gal-T cDNA was randomlabeled and hybridized to a human multiple tissue Northern blot; each lane contained 2 g of poly(A) ϩ RNA from the indicated tissue. The filter was washed at 65°C in 0.1ϫ SSC, 0.1% SDS and exposed for 18 h. B, Northern blot analysis of rat core 1 ␤3-Gal-transferase transcripts. Northern analysis was performed as described for the human blot, except the probe was the rat cDNA. a product with an unexpected size of ϳ650 bp instead of the expected 704 bp. However, the 3Ј portion (520 bp) of the 650-bp product did match perfectly within the expected 704-bp product, but the remaining 130 bp did not match with any sequence. We then used the matching 520-bp sequence for BlastN searching in the data base, and we identified a C. elegans EST that contained a sequence corresponding to correct 5Ј end of the cDNA. With this information PCR was then performed on the C. elegans cDNA library as a template using 5Ј primer and 3Ј primer corresponding to the predicted full-length cDNA with 1,170 bp that include the stop TAA. The sequence of the PCR product was obtained, and the translated sequence is shown in FIG. 7 . Comparison of human, rat, mouse, fly, and nematode core 1 ␤3-Gal-Ts. ClustalW alignment of the putative protein sequences. Identical residues are indicated by boxes. Gaps in the sequences are indicated by hyphens. Sequences were identified as described under "Experimental Procedures." Fig. 7 . The presence of this sequence in a cDNA library strongly suggests the predicted gene is actually expressed. The C. elegans core 1 ␤3-Gal-T is predicted to contain 389 amino acids (Fig. 7) . Overall, the protein is 42.7% identical to the human protein.
(The C. elegans mRNA sequence has been deposited in GenBank TM as accession number AF269063.) Homologous sequences from D. melanogaster were identified by data base searching, but they were not physically cloned. Two highly homologous Drosophila sequences were identified by data base searching. The Drosophila core 1 ␤3-Gal-T was identified by BlastP searching using the human protein sequence. A predicted protein of 388 amino acids contained in gbAAF52723.1 was identified that was 43% identical to the human protein sequence. A second homologous Drosophila sequence was similarly identified as the CG8708 gene product (gbAAF59121.1). Analysis of the predicted protein suggested the carboxyl-terminal portion of this protein was incorrectly predicted. The correct sequence was identified by searching the genomic sequence. This sequence predicted a protein of 366 amino acids that is 41.3% identical to the human sequence. The two Drosophila sequences are very similar at the amino terminus but are significantly different at the carboxyl terminus, suggesting that the two proteins may differ in the catalytic activity or substrate interactions.
Genomic Structure of Human Core 1 ␤3-Gal-T-The cDNA sequence of human core 1 ␤3-Gal-T was used for a BlastN nr (non-redundant) search, which identified the Homo sapiens PAC (P-1-derived artificial chromosome) clone DJ0733B09 from 7p14-p13 (GenBank TM accession number AC005532). The sequence of this clone predicts a gene containing 115,954 bp. Analysis of its sequence compared with the cDNA sequences of human core 1 ␤3-Gal-T shows that the human core 1 ␤3-Gal-T gene contains 3 exons (Fig. 8) . Exon I is derived from 64,041 to 64,260 with a size of 220 bp. Exon II is from 67,976 to 68,643 with a size of 668 bp. Exon III is from 73,245 to 73,448 with a size of 204 bp.
DISCUSSION
In the present study, we used the amino acid sequence of the purified rat liver core 1 ␤3-Gal-T to clone and express the cDNA encoding human core 1 ␤3-Gal-T. Core 1 ␤3-Gal-T is a key glycosyltransferase catalyzing the formation of the core 1 structure Gal␤133GalNAc␣1-R, which can be further elongated to form complex O-glycans. The deduced primary structure of the core 1 ␤3-Gal-T predicts a type II transmembrane topology similar to previously described glycosyltransferases. Expression of an epitope-tagged version lacking the putative transmembrane domain generated a soluble epitope-tagged enzyme with a size nearly identical to that predicted by the sequence of the cDNA, confirming the type II topology.
To confirm that the gene identified as encoding the human core 1 ␤3-Gal-T actually encodes a catalytically active enzyme, we assayed the full-length and HPC4 epitope-tagged soluble forms of the enzyme for core 1 ␤3-Gal-T activity. Treatment of the reaction products with O-glycosidase, which is specific for the core 1 disaccharide structure, quantitatively released the disaccharide. These results demonstrate that the HPC4 epitope-tagged soluble form of the enzyme is active and generates the expected product.
Interestingly, the human core 1 ␤3-Gal-T lacks N-glycosylation sequons, which is unusual, given that most previously described glycosyltransferases are N-glycosylated glycoproteins (26) . The epitope-tagged core 1 ␤3-Gal-T expressed in Lec1, CHO parent cells, and 293T cells generated similarly sized proteins, with apparent sizes similar to the predicted size from the amino acid sequence. These results strongly suggest that there are no significant post-translational modifications of the core 1 ␤3-Gal-T. Although the sequence of the vertebrate core 1 ␤3-Gal-T does not predict any N-glycosylation sequons, the sequence of the C. elegans core 1 ␤3-Gal-T predicts four N-glycosylation sequons, and two are contiguous -Asn (84)-AsnSer-Ser-. Whether any of these sites in the C. elegans enzyme are N-glycosylated is not yet known. Consistent with the widespread occurrence of core 1 ␤3-Gal-T activity, we found that transcripts for the enzyme occur in all tissues examined, but expression in humans was highest in kidney, placenta, heart, and liver. The differential expression of the transcript for the core 1 ␤3-Gal-T is consistent with a high degree of regulation of expression of this enzyme. Studies on the distribution of the core 1 ␤3-Gal-T activity confirm that activity is widely expressed in many cells and tissues, but the activity varies (1, 4) .
Although expression of the core 1 ␤3-Gal-T is considered ubiquitous in mammalian cells, its expression is probably highly regulated. Tn antigen is expressed on glycoproteins from T-lymphoid cells, including Jurkat and Molt-4 (27, 28) , consistent with the low level of core 1 ␤3-Gal-T activity in Jurkat cells (27) . Human colonic cancer cell lines express the sialyl-Tn antigen NeuAc␣2-6GalNAc␣1-Ser/Thr, partly due to lack of the core 1 ␤3-Gal-T activity (29) . The synthesis of the core 1 O-glycan structure by the core 1 ␤3-Gal-T is perhaps competitive with synthesis of the core 3 O-glycan structure GlcNAc␤133GalNAc-R by the core 3 ␤3-N-acetylglucosaminyltransferase and the NeuAc␣236GalNAc-␣-R by the ␣2-6-sialyltransferase. Differential expression and subcompartmentalization of these activities may account for the regulated expression of mucin core structures, but much remains to be learned about the factors regulating expression of the relevant enzymes for generating O-glycan core structures and their polypeptide acceptors.
Because complex O-glycans have been described in many different animals, the core 1 ␤3-Gal-T enzyme is expected to have a wide distribution. Data base searches and cloning experiments identified highly homologous sequences in rat, mouse, Drosophila, and nematodes. When the proteins predicted by these sequences were aligned, the putative catalytic domains were found to be highly conserved in several regions including amino acids 102-134, 161-180, 191-224, and 254 -311 (human numbering). The mammalian enzymes are highly homologous and nearly identical, whereas the non-mammalian enzymes demonstrate more divergence. The cytoplasmic domains, transmembrane domains, and stem regions display significantly less homology as might be expected. All six cysteine residues predicted to be in the lumenal domain are completely conserved in all of the homologous sequences. The mammalian sequences contain two additional cysteine residues in the transmembrane domain that are not present in the other species. The nature and positions of the intramolecular and intermolecular disulfide bonds are presently unknown. The purified rat liver core 1 ␤3-Gal-T was found to occur as a disulfidebonded dimer, but active monomeric forms were also identified (33) .
The protein we describe has homology to a protein predicted to be encoded by the mRNA derived from the gene ␤3Gx-T9 described by Amado et al. (30) , which more recently has been designated ␤3-Gal-T8 (GenBank TM accession number FIG. 8 . Genomic structure of the human core 1 ␤3-Gal-T gene. The human core 1 ␤3-Gal-T gene is arranged as three exons that are contained within the sequence of PAC clone DJ0733B09 from 7p14-p13. AJ132443). Both the human core 1 ␤3-Gal-T described here and the ␤3-Gal-T8 are encoded by a gene located at 7p14-p13. However, the ␤3-Gal-T8 gene is predicted to contain only two exons, whereas the human core 1 ␤3-Gal-T gene contains three exons. This difference may arise because the ␤3-Gal-T8 sequence described to date is incomplete at the 3Ј end, and some sequence reported for the protein is predicted from what we have determined to be derived from an intron between exons 2 and 3. The putative ␤3-Gal-T8 mRNA is predicted to encode a protein containing only 309 amino acids with 4 Cys residues in the luminal domain. The core 1 ␤3-Gal-T, by contrast, contains 363 amino acids with 6 Cys residues in the luminal domain. The uncertainty regarding the 3Ј sequence of the ␤3-Gal-T8 probably led to the conclusion that the gene has only two exons. However, it is likely that the ␤3-Gal-T8 gene and the gene we describe to encode the core 1 ␤3-Gal-T are the same genes.
Comparison of the human core 1 ␤3-Gal-T sequence with that of the previously described (30) ␤3-galactosyltransferase family demonstrates no overall apparent homology. However, sequences similar to four of the six identified conserved motifs in the ␤3-galactosyltransferase family can be identified in the core 1 ␤3-Gal-T sequence, namely the VKXTW, DXDXF, GX-GYV(I)XS, and DLXXG motifs (Fig. 7) . All eight of the previously described ␤3-galactosyltransferases each contain all six of these motifs. Interestingly, the core 1 ␤3-Gal-T sequence does not share the Cys residues that are found in all members of the ␤3-galactosyltransferase family. No homology with the seven-member ␤4-galactosyltransferase family could be demonstrated. These results suggest that the core 1 ␤3-Gal-T identified in this study may be distantly related to the ␤3-galactosyltransferase family.
In marked contrast to the previously described ␤-galactosyltransferase families encompassing many highly homologous genes, only a single human core 1 ␤3-Gal-T was identified by sequence homology searching. Given the completeness of the data bases, it seems unlikely an additional human homolog of the core 1 ␤3-Gal-T will be identified.
It has been postulated that Tn syndrome and IgA nephropathy result from a stem cell mutation leading to deficiency of core 1 ␤3-Gal-T (6 -11). These diseases could result from mutations in the structural gene for the core 1 ␤3-Gal-T or could be due to repression of the gene expression (11) . Cloned T-cells derived from patients with Tn syndrome lack core 1 ␤3-Gal-T, but activity could be elevated by treatment of cells with 5-azacytidine or sodium n-butyrate, both inducers of gene expression (11) . IgA from patients with IgA nephropathy are deficient in the core 1 O-glycan structure in the hinge region, and expression of Tn antigen (31) and core 1 ␤3-Gal-T is reduced ϳ30% in lymphocytes from patients with IgA nephropathy (9) . However, the hinge region of the IgA may be underglycosylated through lack of the core N-acetylgalactosamine, and this may also contribute to antigenic recognition of the altered IgA (32) .
The existence of Tn syndrome and IgA nephropathy, both of which have been proposed to result from somatic mutations in core 1 ␤3-Gal-T, is consistent with the hypothesis that only a single gene encoding the core 1 ␤3-Gal-T is found in humans. Further studies, now in progress, will be required to determine whether mutations in the structural gene encoding the core 1 ␤3-Gal-T or dysregulation of the expression and/or subcellular localization of the enzyme are responsible for Tn syndrome or IgA nephropathy.
